Ginkgo Bioworks Holdings, Inc.
DNAGinkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
DNA Earnings Report
FQ end 2026-06 | Call: 2026-08-05 15:00:00
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Ginkgo Bioworks Holdings, Inc.'s next FDA catalyst?→
Ginkgo Bioworks Holdings, Inc.'s (DNA) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DNA biotech catalysts?→
Add DNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ginkgo Bioworks Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.